UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53
UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $53.
Stocks · News reference
Nektar Therapeutics Presents Data On Rezpegaldesleukin From Its Phase 2b REZOLVE-A, Phase 2b REZOLVE-AD Trials At European Academy Of Dermatology And Venereology
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130
Leerink Partners analyst Will Soghikian initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Outperform rating and announces Price Target of $130.
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating